• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

为何赛马行业和马术项目需要应用群体药代动力学:为了学习、解释、总结、协调和个体化。

Why the racing industry and equestrian disciplines need to implement population pharmacokinetics: To learn, explain, summarize, harmonize, and individualize.

作者信息

Toutain Pierre-Louis

机构信息

INTHERES, Université de Toulouse, INRAE, ENVT, Toulouse, France.

The Royal Veterinary College, University of London, London, UK.

出版信息

Drug Test Anal. 2025 Feb;17(2):250-258. doi: 10.1002/dta.3706. Epub 2024 Apr 29.

DOI:10.1002/dta.3706
PMID:38685692
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11842173/
Abstract

Population pharmacokinetics (POP PK) is a powerful pharmacokinetic tool, which measures quantitatively, and explains the variability in drug exposure and drug effect between individuals. POP PK uses an observational (nonexperimental) approach; it is conducted in the target population living in its normal environment (e.g., farm and race-track). The strength of the POP PK approach lies in its greater relevance for the population studied in its different natural environments than experimental studies carried out in more or less biased laboratory conditions. In clinical settings, it is commonly necessary to restrict the number of samples per subject collected for analysis and the derived data cannot be analyzed using traditional individual data analytical methods; rather data are merged and analyzed with an appropriate statistical tool: the nonlinear mixed effect model (NLMEM). POP PK modeling is frequently used with the objective of adjusting drug dosage, and hence drug exposure, not only for the whole population but also for subgroups of animals (e.g., for a given breed, sex, and age). It can also have application at the individual subject level, in the context of precision medicine. For horses, the use of the POP PK/PD model will allow prescribers to estimate an individual Withdrawal Time for a given horse whose treatment they are supervising. Another potential field of application will be meta-analysis of existing data to generate new knowledge on a drug or to collate and synthesize, in an objective and transparent manner, existing data; this will facilitate harmonization of screening limits at an international level.

摘要

群体药代动力学(POP PK)是一种强大的药代动力学工具,它可以进行定量测量,并解释个体之间药物暴露和药物效应的变异性。POP PK采用观察性(非实验性)方法;它是在目标人群生活的正常环境(如农场和赛马场)中进行的。POP PK方法的优势在于,与在或多或少存在偏差的实验室条件下进行的实验研究相比,它与在不同自然环境中研究的人群具有更大的相关性。在临床环境中,通常有必要限制为分析而收集的每个受试者的样本数量,并且无法使用传统的个体数据分析方法对所得数据进行分析;相反,数据会合并并使用适当的统计工具进行分析:非线性混合效应模型(NLMEM)。POP PK建模经常用于调整药物剂量的目的,从而不仅针对整个人群,而且针对动物亚组(例如特定品种、性别和年龄)调整药物暴露。在精准医学的背景下,它也可以应用于个体受试者层面。对于马匹,使用POP PK/PD模型将使开处方者能够为其正在监督治疗的特定马匹估计个体停药时间。另一个潜在的应用领域将是对现有数据进行荟萃分析,以产生关于一种药物的新知识,或以客观和透明的方式整理和综合现有数据;这将有助于在国际层面协调筛查限值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3ee/11842173/733c4d3e5ce3/DTA-17-250-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3ee/11842173/f99ea3cee201/DTA-17-250-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3ee/11842173/733c4d3e5ce3/DTA-17-250-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3ee/11842173/f99ea3cee201/DTA-17-250-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3ee/11842173/733c4d3e5ce3/DTA-17-250-g002.jpg

相似文献

1
Why the racing industry and equestrian disciplines need to implement population pharmacokinetics: To learn, explain, summarize, harmonize, and individualize.为何赛马行业和马术项目需要应用群体药代动力学:为了学习、解释、总结、协调和个体化。
Drug Test Anal. 2025 Feb;17(2):250-258. doi: 10.1002/dta.3706. Epub 2024 Apr 29.
2
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
3
Bayesian Population Physiologically-Based Pharmacokinetic (PBPK) Approach for a Physiologically Realistic Characterization of Interindividual Variability in Clinically Relevant Populations.基于贝叶斯群体生理药代动力学(PBPK)方法对临床相关群体个体间变异性进行生理现实特征描述
PLoS One. 2015 Oct 2;10(10):e0139423. doi: 10.1371/journal.pone.0139423. eCollection 2015.
4
Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development.药物计量学:用于改善临床药物开发决策的建模与模拟工具。
Eur J Drug Metab Pharmacokinet. 2000 Jan-Mar;25(1):49-58. doi: 10.1007/BF03190058.
5
Pharmacokinetics of tiludronate in horses: A field population study.替鲁膦酸盐在马体内的药代动力学:一项现场群体研究。
Equine Vet J. 2018 Jul;50(4):488-492. doi: 10.1111/evj.12789. Epub 2018 Jan 9.
6
A framework for meta-analysis of veterinary drug pharmacokinetic data using mixed effect modeling.使用混合效应模型对兽药药代动力学数据进行Meta分析的框架。
J Pharm Sci. 2015 Apr;104(4):1230-9. doi: 10.1002/jps.24341. Epub 2015 Jan 12.
7
Nonparametric Methods in Population Pharmacokinetics.群体药代动力学中的非参数方法
J Clin Pharmacol. 2022 Feb;62(2):142-157. doi: 10.1002/jcph.1650. Epub 2020 Oct 26.
8
Population Pharmacokinetic (Pop-PK) Analysis of Torsemide in Healthy Korean Males Considering CYP2C9 and OATP1B1 Genetic Polymorphisms.考虑CYP2C9和OATP1B1基因多态性的健康韩国男性中托拉塞米的群体药代动力学(Pop-PK)分析。
Pharmaceutics. 2022 Apr 1;14(4):771. doi: 10.3390/pharmaceutics14040771.
9
Investigating the contribution of residual unexplained variability components on bias and imprecision of parameter estimates in population pharmacokinetic mixed-effects modeling.在群体药代动力学混合效应模型中,研究残留未解释变异成分对参数估计偏差和不精密度的影响。
J Pharmacokinet Pharmacodyn. 2023 Apr;50(2):123-132. doi: 10.1007/s10928-022-09837-5. Epub 2023 Jan 8.
10
The role of population PK-PD modelling in paediatric clinical research.群体 PK-PD 模型在儿科临床研究中的作用。
Eur J Clin Pharmacol. 2011 May;67 Suppl 1(Suppl 1):5-16. doi: 10.1007/s00228-009-0782-9. Epub 2010 Mar 26.

引用本文的文献

1
Population Pharmacokinetics and Model-Informed Precision Dosing of Clobazam Based on the Developmental and Genetic Characteristics of Children with Epilepsy.基于癫痫患儿发育和遗传特征的氯巴占群体药代动力学及模型引导的精准给药
Pharmaceutics. 2025 Jun 23;17(7):813. doi: 10.3390/pharmaceutics17070813.
2
Rational quinidine dosage regimen for atrial fibrillation in Thoroughbred racehorses based on population pharmacokinetics.基于群体药代动力学的纯种赛马房颤合理奎尼丁给药方案
Front Vet Sci. 2024 Oct 7;11:1454342. doi: 10.3389/fvets.2024.1454342. eCollection 2024.

本文引用的文献

1
Pharmacokinetic-pharmacodynamic cutoff values for benzylpenicillin in horses to support the establishment of clinical breakpoints for benzylpenicillin antimicrobial susceptibility testing in horses.马体内苄青霉素的药代动力学-药效学截断值,用于支持建立马的苄青霉素抗菌药物敏感性试验的临床断点。
Front Microbiol. 2023 Oct 25;14:1282949. doi: 10.3389/fmicb.2023.1282949. eCollection 2023.
2
Requirements, expectations, challenges and opportunities associated with training the next generation of pharmacometricians.培养下一代药物计量学家所涉及的要求、期望、挑战与机遇。
CPT Pharmacometrics Syst Pharmacol. 2023 Jul;12(7):883-888. doi: 10.1002/psp4.12970. Epub 2023 May 2.
3
Pharmacokinetic analysis across studies to drive knowledge-integration: A tutorial on individual patient data meta-analysis (IPDMA).
跨研究的药代动力学分析以推动知识整合:个体患者数据荟萃分析(IPDMA)教程。
CPT Pharmacometrics Syst Pharmacol. 2023 Sep;12(9):1187-1200. doi: 10.1002/psp4.13002. Epub 2023 Jun 11.
4
Model-based meta-analysis of salbutamol pharmacokinetics and practical implications for doping control.基于模型的沙丁胺醇药代动力学的荟萃分析及其在兴奋剂控制中的实际意义。
CPT Pharmacometrics Syst Pharmacol. 2022 Apr;11(4):469-481. doi: 10.1002/psp4.12773. Epub 2022 Mar 22.
5
Free and Open-Source Posologyr Software for Bayesian Dose Individualization: An Extensive Validation on Simulated Data.用于贝叶斯剂量个体化的免费开源剂量学软件:对模拟数据的广泛验证
Pharmaceutics. 2022 Feb 18;14(2):442. doi: 10.3390/pharmaceutics14020442.
6
Medication control of flunixin in racing horses: Possible detection times using Monte Carlo simulations.赛马中氟尼辛的药物控制:使用蒙特卡罗模拟的可能检测时间。
Equine Vet J. 2022 Sep;54(5):979-988. doi: 10.1111/evj.13532. Epub 2021 Nov 25.
7
Personalized Medicine of Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacogenetics, Therapeutic Drug Monitoring, and Beyond.炎症性肠病中单克隆抗体的个性化医疗:药物遗传学、治疗药物监测及其他。
Front Pharmacol. 2021 Feb 8;11:610806. doi: 10.3389/fphar.2020.610806. eCollection 2020.
8
Determination of the pharmacokinetic-pharmacodynamic cut-off values of marbofloxacin in horses to support the establishment of a clinical breakpoint for antimicrobial susceptibility testing.测定马波沙星在马体内的药代动力学-药效学 cutoff 值,以支持建立用于抗菌药物敏感性试验的临床折点。
Equine Vet J. 2021 Sep;53(5):1047-1055. doi: 10.1111/evj.13385. Epub 2020 Dec 4.
9
Precision Dosing Priority Criteria: Drug, Disease, and Patient Population Variables.精准给药优先标准:药物、疾病及患者群体变量
Front Pharmacol. 2020 Apr 22;11:420. doi: 10.3389/fphar.2020.00420. eCollection 2020.
10
Mathematical modeling and simulation in animal health. Part III: Using nonlinear mixed-effects to characterize and quantify variability in drug pharmacokinetics.动物健康领域的数学建模与模拟。第三部分:使用非线性混合效应来表征和量化药物药代动力学的变异性。
J Vet Pharmacol Ther. 2018 Apr;41(2):171-183. doi: 10.1111/jvp.12473. Epub 2017 Dec 11.